Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.57 +0.64 (+1.31%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

McDonald’s Is Down, But Long-Term Investors Can Still Take a Bite

June 20, 2025

Analysts are downgrading McDonald's and the stock may have further to fall, but as a long-term opportunity, it may be getting to a point of offering real value

Via MarketBeat

How Do Investors Really Feel About Novo Nordisk? ↗

June 19, 2025

Via Benzinga

How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl ↗

June 19, 2025

This dark horse candidate has emerged to take significant share in the weight-loss drugs space.

Via Investor's Business Daily

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - A Strong Candidate for Value Investors ↗

June 19, 2025

NOVO-NORDISK A/S (NYSE:NVO) is a strong value stock with high profitability, solid growth, and an attractive valuation, making it a candidate for long-term investors.

Via Chartmill

Why Scholar Rock Shares Are Soaring Today ↗

June 18, 2025

Via The Motley Fool

Topics Stocks

US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies ↗

June 18, 2025

The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported.

Via Stocktwits

Topics Lawsuit

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study ↗

June 18, 2025

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.

Via Benzinga

Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy? ↗

June 18, 2025

Via The Motley Fool

Topics Artificial Intelligence

Why Novo Nordisk Stock Sank by Nearly 4% Today ↗

June 16, 2025

Via The Motley Fool

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

June 17, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END

Via FinancialNewsMedia

Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor ↗

June 16, 2025

A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic.

Via Benzinga

Topics Intellectual Property

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

June 17, 2025

From FN Media Group LLC

Via GlobeNewswire

3 Growth Stocks You Can Buy Right Now Without Any Hesitation ↗

June 16, 2025

Via The Motley Fool

1 Growth Stock Down 9% to Buy Right Now ↗

June 14, 2025

Via The Motley Fool

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company ↗

June 13, 2025

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.

Via Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗

June 13, 2025

Via Benzinga

Why Novo Nordisk Stock Pumped Higher on Thursday ↗

June 12, 2025

Via The Motley Fool

Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking ↗

June 12, 2025

The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.

Via Stocktwits

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 12, 2025

Via Benzinga

Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills ↗

June 12, 2025

Nvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical workflows.

Via Benzinga

4 Dividend Stocks to Double Up on Right Now ↗

June 12, 2025

The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous dividend winners.

Via The Motley Fool

Topics Artificial Intelligence

2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility ↗

June 12, 2025

Via The Motley Fool

Topics Artificial Intelligence Government

Should You Buy UnitedHealth Stock Instead of Novo Nordisk Stock? ↗

June 12, 2025

Via The Motley Fool

McDonald's Just Got Hammered By Weight-Loss Drugs — Twice ↗

June 11, 2025

McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned.

Via Benzinga

Nvidia Extends AI Reach In Europe With Alliances ↗

June 11, 2025

Nvidia announced a flurry of alliances with European companies and governments that extend its influence in AI across the continent.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels ↗

June 11, 2025

Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.

Via Stocktwits

Topics Artificial Intelligence Economy

Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies ↗

June 11, 2025

Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.

Via Benzinga

Why Novo Nordisk Stock Just Popped ↗

June 10, 2025

Novo Nordisk stock has multiple catalysts that could soon reverse is slide.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

June 10, 2025

Via Benzinga

2 Weight Loss Drug Stocks That Are Screaming Buys in June ↗

June 10, 2025

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Via The Motley Fool

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today